HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
08 Apr 2024 09:30 AM
RNS
2023 Annual Report and Notice of AGM
05 Apr 2024 09:30 AM
RNS
Data to be Presented at AACR Congress 2024
02 Apr 2024 07:00 AM
RNS
HUTCHMED and Innovent Announce NDA Acceptance
28 Mar 2024 07:00 AM
RNS
Savolitinib sNDA Accepted in China
22 Mar 2024 07:00 AM
RNS
Initiation of Registration Stage of P2/3 Trial
14 Mar 2024 09:00 AM
RNS
LTIP and Share Option Scheme
05 Mar 2024 08:30 AM
RNS
Vesting of awards under the LTIP
28 Feb 2024 12:45 PM
RNS
Publication of Form 20-F
28 Feb 2024 11:30 AM
RNS
2023 Full Year Results and Business Updates
07 Feb 2024 07:00 AM
RNS
Presentation of Phase III Data on Fruquintinib
02 Feb 2024 08:37 AM
RNS
Inmagene Exercises Option for Two Drug Candidates
01 Feb 2024 08:30 AM
RNS
HUTCHMED to Announce 2023 Final Results
30 Jan 2024 07:12 AM
RNS
HUTCHMED Receives Marketing Approval in Hong Kong
11 Jan 2024 07:00 AM
RNS
Sovleplenib NDA Granted Priority Review in China
29 Dec 2023 08:30 AM
RNS
Total Voting Rights
29 Dec 2023 08:30 AM
RNS
Blocklisting Six Monthly Return
21 Dec 2023 10:00 AM
RNS
Overseas Regulatory Announcement
13 Dec 2023 07:00 AM
RNS
Inclusion in National Reimbursement Drug List
13 Dec 2023 07:00 AM
RNS
Completed Enrollment of Phase II/III Trial
07 Dec 2023 10:04 AM
RNS
Overseas Regulatory Announcement
01 Dec 2023 07:00 AM
RNS
Clinical Data to be Presented at Congresses
30 Nov 2023 08:30 AM
RNS
Total Voting Rights
09 Nov 2023 07:00 AM
RNS
U.S. FDA Approval of FRUZAQLA™ (fruquintinib)
24 Oct 2023 09:30 AM
RNS
Vesting of awards under the LTIP
16 Oct 2023 09:30 AM
RNS
Clinical Data to be Presented at ESMO 2023
29 Sep 2023 09:30 AM
RNS
Total Voting Rights
29 Sep 2023 09:30 AM
RNS
NDA Submission for Fruquintinib in Japan
14 Sep 2023 09:30 AM
RNS
Director’s Share Dealing
14 Sep 2023 09:30 AM
RNS
Director’s Share Dealing
12 Sep 2023 09:30 AM
RNS
Phase IIIb Savolitinib Results at WCLC 2023
12 Sep 2023 07:00 AM
RNS
Patient Enrollment Completed for Bridging Study
31 Aug 2023 09:30 AM
RNS
Total Voting Rights
29 Aug 2023 07:00 AM
RNS
BTD in China for Savolitinib for Gastric Cancer
21 Aug 2023 07:00 AM
RNS
Sovleplenib Phase 3 Study Meets Primary Endpoint
07 Aug 2023 09:30 AM
RNS
Exercise of Share Options by a Director
31 Jul 2023 12:00 PM
RNS
Interim Results and Business Updates
20 Jul 2023 07:00 AM
RNS
Breakthrough Therapy Designation for Fruquintinib
13 Jul 2023 09:30 AM
RNS
Changes to Board and Technical Committee
10 Jul 2023 07:00 AM
RNS
Phase 1 Study of HMPL-415 Initiated
29 Jun 2023 09:30 AM
RNS
Blocklisting Six Monthly Return
26 Jun 2023 09:30 AM
RNS
HUTCHMED to Announce 2023 Half-Year Results
16 Jun 2023 07:00 AM
RNS
Phase III FRESCO-2 Results in The Lancet
15 Jun 2023 03:39 PM
RNS
MAA of Fruquintinib Validated by the EMA
09 Jun 2023 10:30 AM
RNS
HUTCHMED Highlights Presentations at EHA and ICML
06 Jun 2023 10:00 AM
RNS
LTIP and Share Option Scheme
31 May 2023 09:30 AM
RNS
Total Voting Rights
26 May 2023 07:00 AM
RNS
Fruquintinib NDA Granted Priority Review by FDA
26 May 2023 07:00 AM
RNS
HUTCHMED Highlights Presentations at ASCO 2023
17 May 2023 09:30 AM
RNS
Standard form for notification of major holdings
12 May 2023 01:15 PM
RNS
Annual General Meeting Poll Results

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings